A Phase 1 interventional study of Nintedanib 150 MG [Ofev] in Drug Interactions, sponsored by PureTech. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by PureTech · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pulmonary Fibrosis with a site in Australia — 5 open to participants now, 10 under way, 3 of them phase 3. Pulmonary Fibrosis · Australia.
Among the 26 studies in Pulmonary Fibrosis with a site in Australia, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2024, is one of 4 in phase 1, and was the 24th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →5 of the 26 studies in Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:
Contineum Therapeutics · Sites in Australia, Argentina, Belgium and 16 more countries
Ages 40+
The University of Western Australia · Sites in Australia
Ages 18+
University of Sydney · Sites in Australia
Ages 18+
University of Sydney · Sites in Australia
Ages 18+
Bristol-Myers Squibb · Sites in Australia, United States, Argentina and 24 more countries
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 5
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 206 across the 24 interventional studies, 308 across the 2 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
PureTech has 4 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Pulmonary Fibrosis with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06626438The University of Western AustraliaTreatable Traits in Interstitial Lung Disease | 2026-12 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
| NCT06122233University of SydneyA Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Pulmonary Fibrosis with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
The purpose of this research is to investigate the effects of deupirfenidone (LYT-100) when co-administered with nintedanib to determine if there are any drug-drug interactions. In particular, the study will investigate the safety, tolerability and pharmacokinetics of LYT-100 co-administered with nintedanib. Eligible participants will be admitted to the Clinical Research Unit for 31 days, will be administered nintedanib and/or LYT-100 for 30 days, and will provide blood samples and have assessments during this time. Participants will return for a safety follow-up visit 30 days after taking the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs (measured in sitting position after 5 minutes' rest) at Screening and at Day -1:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive the same interventions at the same schedule
Drug: Nintedanib 150 MG [Ofev]
Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
Also known as: Deupirfenidone (LYT-100) 275 MG
AUC of LYT-100 and Nintedanib
The area under the curve will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Tmax of LYT-100 and Nintedanib
The time to maximum concentration (Tmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Cmax of LYT-100 and Nintedanib
The maximum observed plasma concentration (Cmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Number of Subjects With Abnormal Vital Signs (Blood Pressure)
Systolic and Diastolic blood pressure measured in millimeters of mercury (mmHg) to determine if there is abnormal blood pressure
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Vital Signs (Heart Rate)
Heart rate is measured in beats per minute (bpm) to determine if there is an abnormal heart rate
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Vital Signs (Respiration Rate)
Respiration rate is measured in breaths per minute (bpm) to determine if the respiration rate is abnormal
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Vital Signs (Body Temperature)
Tympanic body temperature is measured in degrees Celsius to determine if the body temperature is abnormal
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Electrocardiograms
Number of participants with an abnormal ECG and/or that have a QTcF\>450 ms
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Physical Examinations
A physical examination is performed to determine if any physical abnormalities are detected
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Laboratory Values (Hematology)
Hematology parameters to be tested are hemoglobin, hematocrit, erythrocytes, platelets, and leukocytes.
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Laboratory Values (Serum Chemistry)
Serum chemistry parameters to be tested are C-reactive protein, urea, creatinine, total and direct bilirubin, urate, albumin, globulin, alkaline phosphatase, creatine phosphokinase, troponin 1, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Laboratory Values (Coagulation)
Coagulation parameters to be tested are international normalized ratio, prothrombin time, activated partial thromboplastin time
Time frame: Screening through Follow-up Visit on Day 60
Number of Subjects With Abnormal Laboratory Values (Urinalysis)
Urinalysis parameters to be tested are micro protein, nitrite, pH, trial specific gravity, ketone bodies, urobilinogen, blood, urine leukocyte esterase, appearance uri acm, micro glucose, bilirubin
Time frame: Screening through Follow-up Visit on Day 60
| Milestone | DDI Cohort |
|---|---|
| Started | 24 |
| Nintedanib 150 mg (days 1 to 7) | 24 |
| Nintedanib+lyt-100 (days 8 to 20) | 24 |
| Lyt-100 (days 21 to 30) | 24 |
| Completed | 24 |
| Not completed | 0 |
The area under the curve will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
| (h*ng/mL) | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| AUC of LYT-100 and Nintedanib | 206 ± 105 | 257 ± 132 | 37410 ± 16726 | 246 ± 123 | 54348 ± 19118 | 51998 ± 17709 |
The time to maximum concentration (Tmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
| hours | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Tmax of LYT-100 and Nintedanib | 2.50 ± 0 | 5.92 ± 0 | 2.00 ± 0 | 2.50 ± 0 | 2.00 ± 0 | 2.00 ± 0 |
The maximum observed plasma concentration (Cmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.
| ng/mL | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Cmax of LYT-100 and Nintedanib | 36.1 ± 20.3 | 38.7 ± 22.0 | 8845 ± 3500 | 37.2 ± 18.9 | 12669 ± 3606 | 12581 ± 3371 |
Systolic and Diastolic blood pressure measured in millimeters of mercury (mmHg) to determine if there is abnormal blood pressure
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Vital Signs (Blood Pressure) | 0 | 0 | 0 | 0 | 0 | 0 |
Heart rate is measured in beats per minute (bpm) to determine if there is an abnormal heart rate
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Vital Signs (Heart Rate) | 0 | 0 | 0 | 0 | 0 | 0 |
Respiration rate is measured in breaths per minute (bpm) to determine if the respiration rate is abnormal
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Vital Signs (Respiration Rate) | 0 | 0 | 0 | 0 | 0 | 0 |
Tympanic body temperature is measured in degrees Celsius to determine if the body temperature is abnormal
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Vital Signs (Body Temperature) | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with an abnormal ECG and/or that have a QTcF\>450 ms
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Electrocardiograms | 0 | 0 | 0 | 0 | 0 | 0 |
A physical examination is performed to determine if any physical abnormalities are detected
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Physical Examinations | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters to be tested are hemoglobin, hematocrit, erythrocytes, platelets, and leukocytes.
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Laboratory Values (Hematology) | 0 | 0 | 0 | 0 | 0 | 0 |
Serum chemistry parameters to be tested are C-reactive protein, urea, creatinine, total and direct bilirubin, urate, albumin, globulin, alkaline phosphatase, creatine phosphokinase, troponin 1, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Laboratory Values (Serum Chemistry) | 1 | 0 | 0 | 0 | 0 | 1 |
Coagulation parameters to be tested are international normalized ratio, prothrombin time, activated partial thromboplastin time
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Laboratory Values (Coagulation) | 0 | 0 | 0 | 0 | 0 | 0 |
Urinalysis parameters to be tested are micro protein, nitrite, pH, trial specific gravity, ketone bodies, urobilinogen, blood, urine leukocyte esterase, appearance uri acm, micro glucose, bilirubin
| Participants | A. Nintedanib 150 mg (Days 1 to 7) | C. Nintedanib 150 mg (Days 11 to 13) | C. LYT100 550 mg (Days 11 to 13) | D. Nintedanib 150mg (Days 14 to 20) | D. LYT100 825 mg (Days 14 to 20) | E. LYT100 825 mg (Days 21 to 30) |
|---|---|---|---|---|---|---|
| Number of Subjects With Abnormal Laboratory Values (Urinalysis) | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Screening through Follow-up Visit on Day 60. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib 150 mg q12h (Days 1 to 7) | 0/24 (0%) | 0/24 (0%) | 7/24 (29.2%) |
| Nintedanib + LYT-100 150 mg q12h + TID (Days 8 to 20) | 0/24 (0%) | 0/24 (0%) | 17/24 (70.8%) |
| LYT-100 825 mg TID (Days 21 to 30) | 0/22 (0%) | 0/22 (0%) | 10/22 (45.5%) |
| Overall | 0/24 (0%) | 0/24 (0%) | 21/24 (87.5%) |
| Event | Nintedanib 150 mg q12h (Days 1 to 7) | Nintedanib + LYT-100 150 mg q12h + TID (Days 8 to 20) | LYT-100 825 mg TID (Days 21 to 30) | Overall |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/24 | 10/24 | 2/22 | 14/24 |
| HeadacheNervous system disorders | 2/24 | 6/24 | 4/22 | 9/24 |
| Abdominal PainGastrointestinal disorders | 2/24 | 5/24 | 1/22 | 7/24 |
| DiarrhoeaGastrointestinal disorders | 3/24 | 4/24 | 0/22 | 7/24 |
| DyspepsiaGastrointestinal disorders | 0/24 | 5/24 | 2/22 | 5/24 |
| VomitingGastrointestinal disorders | 1/24 | 1/24 | 1/22 | 3/24 |
| PresyncopeNervous system disorders | 0/24 | 2/24 | 1/22 | 3/24 |
| DizzinessNervous system disorders | 0/24 | 2/24 | 0/22 | 2/24 |
| Upper respiratory infectionsInfections and infestations | 1/24 | 1/24 | 0/22 | 2/24 |
| Aphthous ulcerGastrointestinal disorders | 0/24 | 0/24 | 1/22 | 1/24 |
| Age, Categorical(Participants) | DDI Cohort |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | DDI Cohort |
|---|---|
| Female | 3 |
| Male | 21 |
| Race (NIH/OMB)(Participants) | DDI Cohort |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Ethnicity (NIH/OMB)(Participants) | DDI Cohort |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | DDI Cohort |
|---|---|
| Australia | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2024 to primary completion in Feb 2025, 2 months.
Results were first posted in Aug 2026, 1 year 5 months after primary completion.
Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
PureTech